Drugs / VXA G2.4 NS-T
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06944717 | Mar 2025 → May 2026 overdue | norovirus infectious disease | Vaxart | Active not recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VXA-G2.4-NS-T | “Healthy participants will receive VXA-G1.1-NN-T (1x10\^11 IU) and VXA-G2.4-NS-T (1x10\^11 IU) orally.” NCT06944717 ↗ |
| Modality | Vaccine | “Next generation vaccine, administered orally.” NCT06944717 ↗ |
| Route | Oral | “Next generation vaccine, administered orally.” NCT06944717 ↗ |